156 related articles for article (PubMed ID: 32386990)
21. Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the diagnosis of pancreatic cancer.
Ohuchida K; Mizumoto K; Ogura Y; Ishikawa N; Nagai E; Yamaguchi K; Tanaka M
Clin Cancer Res; 2005 Mar; 11(6):2285-92. PubMed ID: 15788678
[TBL] [Abstract][Full Text] [Related]
22. Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy.
Hisatomi H; Nagao K; Kanamaru T; Endo H; Tomimatsu M; Hikiji K
Int J Oncol; 1999 Apr; 14(4):727-32. PubMed ID: 10087321
[TBL] [Abstract][Full Text] [Related]
23. Expression of telomerase component genes in hepatocellular carcinomas.
Takahashi S; Kitamoto M; Takaishi H; Aikata H; Kawakami Y; Nakanishi T; Shimamoto F; Tahara E; Tahara H; Ide T; Kajiyama G
Eur J Cancer; 2000 Mar; 36(4):496-502. PubMed ID: 10717526
[TBL] [Abstract][Full Text] [Related]
24. Telomerase reverse transcriptase gene amplification in hepatocellular carcinoma.
Takuma Y; Nouso K; Kobayashi Y; Nakamura S; Tanaka H; Matsumoto E; Fujikawa T; Suzuki M; Hanafusa T; Shiratori Y
J Gastroenterol Hepatol; 2004 Nov; 19(11):1300-4. PubMed ID: 15482538
[TBL] [Abstract][Full Text] [Related]
25. Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease.
Kojima H; Yokosuka O; Imazeki F; Saisho H; Omata M
Gastroenterology; 1997 Feb; 112(2):493-500. PubMed ID: 9024303
[TBL] [Abstract][Full Text] [Related]
26. Oxidative stress may enhance the malignant potential of human hepatocellular carcinoma by telomerase activation.
Nishikawa T; Nakajima T; Katagishi T; Okada Y; Jo M; Kagawa K; Okanoue T; Itoh Y; Yoshikawa T
Liver Int; 2009 Jul; 29(6):846-56. PubMed ID: 19141026
[TBL] [Abstract][Full Text] [Related]
27. Telomerase activity and telomere length in human hepatocellular carcinoma.
Huang GT; Lee HS; Chen CH; Chiou LL; Lin YW; Lee CZ; Chen DS; Sheu JC
Eur J Cancer; 1998 Nov; 34(12):1946-9. PubMed ID: 10023320
[TBL] [Abstract][Full Text] [Related]
28. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Borah S; Xi L; Zaug AJ; Powell NM; Dancik GM; Cohen SB; Costello JC; Theodorescu D; Cech TR
Science; 2015 Feb; 347(6225):1006-10. PubMed ID: 25722414
[TBL] [Abstract][Full Text] [Related]
29. [Studies on telomerase reverse transcriptase components and liver cancer].
Cai JJ; Guo XL
Zhonghua Gan Zang Bing Za Zhi; 2016 Jul; 24(7):555-560. PubMed ID: 27784441
[TBL] [Abstract][Full Text] [Related]
30. Influence of the hTERT rs2736100 polymorphism on telomere length in gastric cancer.
Choi BJ; Yoon JH; Kim O; Choi WS; Nam SW; Lee JY; Park WS
World J Gastroenterol; 2015 Aug; 21(31):9328-36. PubMed ID: 26309358
[TBL] [Abstract][Full Text] [Related]
31. Noncoding telomeric repeat-containing RNA inhibits the progression of hepatocellular carcinoma by regulating telomerase-mediated telomere length.
Cao H; Zhai Y; Ji X; Wang Y; Zhao J; Xing J; An J; Ren T
Cancer Sci; 2020 Aug; 111(8):2789-2802. PubMed ID: 32357278
[TBL] [Abstract][Full Text] [Related]
32. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L; Stummer W; Senner V; Brokinkel B
Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
[TBL] [Abstract][Full Text] [Related]
33. Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing and is associated with long telomeres.
Zaffaroni N; Villa R; Pastorino U; Cirincione R; Incarbone M; Alloisio M; Curto M; Pilotti S; Daidone MG
Clin Cancer Res; 2005 Apr; 11(8):2832-9. PubMed ID: 15837730
[TBL] [Abstract][Full Text] [Related]
34. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
35. Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patients with hepatocellular carcinoma.
Miura N; Shiota G; Nakagawa T; Maeda Y; Sano A; Marumoto A; Kishimoto Y; Murawaki Y; Hasegawa J
Oncology; 2003; 64(4):430-4. PubMed ID: 12759542
[TBL] [Abstract][Full Text] [Related]
36. Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma.
Gertler R; Doll D; Maak M; Feith M; Rosenberg R
Cancer; 2008 May; 112(10):2173-80. PubMed ID: 18348304
[TBL] [Abstract][Full Text] [Related]
37. [Detection of telomerase activity of exfoliated cells in bile and its clinical impact].
Yu SA; Peng CH; Wu RJ; Zheng ZD; Chen K; Fu ZN
Ai Zheng; 2002 Feb; 21(2):177-80. PubMed ID: 12479071
[TBL] [Abstract][Full Text] [Related]
38. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma.
Gertler R; Rosenberg R; Stricker D; Friederichs J; Hoos A; Werner M; Ulm K; Holzmann B; Nekarda H; Siewert JR
J Clin Oncol; 2004 May; 22(10):1807-14. PubMed ID: 15143073
[TBL] [Abstract][Full Text] [Related]
39. Utility of pancreatic digestive enzyme immunohistochemistry in the differential diagnosis of hepatocellular carcinoma, cholangiocarcinoma and metastatic adenocarcinoma of the liver.
Terada T; Nakanuma Y
Pathol Int; 1996 Mar; 46(3):183-8. PubMed ID: 10846568
[TBL] [Abstract][Full Text] [Related]
40. Telomerase and Telomeres Biology in Thyroid Cancer.
Donati B; Ciarrocchi A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31200515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
